From Orlando, Fla., at a meeting of the American Society of Hematology
Patients with leukemia get a fighting chance when they receive a transplant of bone marrow cells from a healthy donor. Unfortunately, immune cells from these new arrivals can run amok in the recipient, creating a life-threatening complication called graft-versus-host disease (GVHD).
Last year, scientists in Sweden trying a new approach to reverse severe GVHD in 16 patients reported some early success (SN: 12/24/05, p. 417: Available to subscribers at Rare marrow cells tackle deadly immune reaction). They gave patients an additional transplant, using only adult mesenchymal stem cells from the marrow. These cells typically become bone, muscle, or other connective tissues but also can develop into a wide variety of other cells.
The researchers now report that 52 people who had severe GVHD after a previous bone marrow transplant have undergone the novel procedure.
Twenty-two of these patients remain alive, half in remarkably good health, says physician Katarina Le Blanc of the Karolinska University Hospital Huddinge in Stockholm. Some have survived more than 3 1/2 years.
"All these patients would have died, and quickly," Le Blanc says. In some patients, the transplanted mesenchymal cells appeared to have immunosuppressive and possibly anti-inflammatory effects that shut down GVHD. There is also evidence that they aided the healing of damaged organs, she says.
Katarina Le Blanc
Centre for Allogeneic Stem-Cell Transplantation
Division of Clinical Immunology
Karolinska University Hospital
SE-141 86, Stockholm
Frank. M.H., and M.H. Sayegh. 2004. Immunomodulatory functions of mesenchymal stem cells. Lancet 363(May 1):1439-1441.
Harder, B. 2005. Rare marrow cells tackle deadly immune reaction. Science News 168(Dec. 24&31):417. Available to subscribers at [Go to].
Le Blanc, K. 2006. Mesenchymal stromal cells: Tissue repair and immune modulation. Cytotherapy 8:559-561.
Le Blanc, K., and O. Ringden. 2006. Mesenchymal stem cells: Properties and role in clinical bone marrow transplantation. Current Opinions in Immunology 18*October):586-591.
Le Blanc, et al. 2004. Treatment of severe acute graft-versus-host disease with third party haploidentical stem cell. Lancet 363:1411-1412.
Ringdén, O., et al. 2006. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81(May 27):1390-1397.
Ringdén, O., et al. 2004. Treatment with granulocyte colony-stimulating factor with allogenic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: A study from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationJournal of Clinical Oncology 22(Feb. 1):416-423.